The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Evaluation of long-term toxicity after chemotherapy for testicular cancer.
Abstract
PURPOSE: The current study evaluates the extent and reversibility of late sequelae after chemotherapy in longterm survivors of testicular cancer. The influence of therapy and patient characteristics and the relationship between different toxicities are assessed. PATIENTS AND METHODS: Ninety patients with a median age of 28 years (range, 19 to 53) and a median followup time of 58 months (range, 15 to 159) participated in the clinical examinations, a personal interview, and technical investigations. Overall health and the impact of late toxicity were assessed by the patients. All patients were in complete remission (CR) for at least 1 year. Chemotherapy had consisted of cisplatin (P), bleomycin (B), and vinblastine (V) in 30 patients (33%); P, B, and etoposide (E) in 26 patients (29%); P, B, E, and a vinca alkaloid in 22 patients (24%); and other P-based combination regimens in 12 patients (13%). RESULTS: Alterations of gonadotropin levels (follicle-stimulating hormone [FSH] luteinizing hormone [LH]) in up to 68% of patients and Leydig cell insufficiency in one third of patients were the most frequently detected abnormalities. Approximately 20% of patients had low serum magnesium [Mg] or phosphate levels, or elevated creatinine levels. Cardiovascular risk factors were identified in one third of patients with elevated serum cholesterol levels with or without obesity; 15% had developed arterial hypertension after chemotherapy. The most frequent symptomatic toxicities were Raynaud's phenomenon (RP) in 30% of patients, ototoxicity in 21%, and peripheral neuropathy in 17%. Major risk factors for the development of toxicity were cumulative dose of P (P < .0001 for ototoxicity and neurotoxicity; P < .01 for overall toxicity, gonadal toxicity, and dehydroepiandrosteron elevation; P < .05 for hypertension and Mg depletion) and type of chemotherapy (57% of PVB-treated patients v25% of PEB +/- vincristine-treated patients with RP; P < .01). CONCLUSION: The cumulative dose of P was a major predictor for toxicity. Patients and treatment characteristics such as noise exposure, age, history of smoking, and mode of B application were less important. Further clinical trials should evaluate the sequelae of chemotherapy treatment for testicular cancer prospectively.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Trends in Cancer Incidence, Survival and Mortality
Estève, J., & Coleman, M. (2009) · Husband and Reznek's Imaging in Oncology, Third Edition · doi:10.3109/9780415874984-2 · Cited by 761
A prospective study of dehydroepiandrosterone sulfate, mortality and cardiovascular disease.
Barrett-Connor, E., Khaw, K.-T., & Yen, S. S. C. (1986) · New England Journal of Medicine · doi:10.1056/nejm198612113152405 · Cited by 681
Gregg, R. W., Molepo, J. M., Monpetit, V. J., Mikael, N. Z., Redmond, D., Gadia, M., & Stewart, D. J. (1992) · Journal of Clinical Oncology · doi:10.1200/jco.1992.10.5.795 · Cited by 358
Bajorin, D. F., Sarosdy, M. F., Pfister, D. G., Mazumdar, M., Motzer, R. J., Scher, H. I., Geller, N. L., Fair, W. R., Herr, H., & Sogani, P. (1993) · Journal of Clinical Oncology · doi:10.1200/jco.1993.11.4.598 · Cited by 354
Raynaud's Phenomenon: A Common Toxicity After Combination Chemotherapy for Testicular Cancer
VOGELZANG, N. J., BOSL, G. J., JOHNSON, K., & KENNEDY, B. J. (1981) · Annals of Internal Medicine · doi:10.7326/0003-4819-95-3-288 · Cited by 296
Nichols, C. R., Williams, S. D., Loehrer, P. J., Greco, F. A., Crawford, E. D., Weetlaufer, J., Miller, M. E., Bartolucci, A., Schacter, L., & Einhorn, L. H. (1991) · Journal of Clinical Oncology · doi:10.1200/jco.1991.9.7.1163 · Cited by 288
Secondary neoplasms following treatment of malignant germ cell tumors.
Bokemeyer, C., & Schmoll, H. (1993) · Journal of Clinical Oncology · doi:10.1200/jco.1993.11.9.1703 · Cited by 145
Self-citationLong-term effects of chemotherapy in patients with testicular cancer.
Osanto, S., Bukman, A., van Hoek, F., Sterk, P. J., de Laat, J. A. P. M., & Hermans, J. (1992) · Journal of Clinical Oncology · doi:10.1200/jco.1992.10.4.574 · Cited by 143
Continuous infusion chemotherapy: a critical review.
Vogelzang, N. J. (1984) · Journal of Clinical Oncology · doi:10.1200/jco.1984.2.11.1289 · Cited by 135
Stoter, G., Koopman, A., Vendrik, C. P. J., Struyvenberg, A., Sleyfer, D. T., Willemse, P. H. B., Koops, H. S., van Oosterom, A. T., Huinink, W. W. T. B., & Pinedo, H. M. (1989) · Journal of Clinical Oncology · doi:10.1200/jco.1989.7.8.1099 · Cited by 118
Cited by
Microtubule-binding agents: a dynamic field of cancer therapeutics
Dumontet, C., & Jordan, M. A. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3253 · Cited by 1,718
Breast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology
Gradishar, W. J., Anderson, B. O., Balassanian, R., Blair, S. L., Burstein, H. J., Cyr, A., Elias, A. D., Farrar, W. B., Forero, A., Giordano, S. H., et al. (2018) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2018.0012 · Cited by 1,609
Chemotherapy-induced peripheral neuropathy: a current review
Staff, N. P., Grisold, A., Grisold, W., & Windebank, A. J. (2017) · Annals of Neurology · doi:10.1002/ana.24951 · Cited by 908
Cardiovascular Morbidity in Long-Term Survivors of Metastatic Testicular Cancer
Meinardi, M. T., Gietema, J. A., van der Graaf, W. T. A., van Veldhuisen, D. J., Runne, M. A., Sluiter, W. J., de Vries, E. G. E., Willemse, P. B. H., Mulder, N. H., van den Berg, M. P., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.8.1725 · Cited by 489
Risk of Second Malignant Neoplasms Among Long-term Survivors of Testicular Cancer
Travis, L. B., Curtis, R. E., Fraumeni, J. F., Boice, J. D., Storm, H., Andersson, M., Hall, P., Bergfeldt, K., Holowaty, E., Clarke, E. A., et al. (1997) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/89.19.1429 · Cited by 488
Metadata
- Authors
- Bokemeyer, C., Berger, C. C., Kuczyk, M. A., & Schmoll, H. J.
- Venue
- Journal of Clinical Oncology
- Published
- 1996-11
- Volume
- 14
- Issue
- 11
- Pages
- 2923-2932
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W1952048380
- Cited by
- 268
- References
- 15
- FWCI
- 6.67
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Evaluation of long-term toxicity after chemotherapy for testicular cancer. https://app.cochat.ai/papers/10.1200/jco.1996.14.11.2923
- The paper
- Bokemeyer, C., Berger, C. C., Kuczyk, M. A., & Schmoll, H. J. (1996). Evaluation of long-term toxicity after chemotherapy for testicular cancer. Journal of Clinical Oncology. https://doi.org/10.1200/jco.1996.14.11.2923
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.